agendia fda approves test for cancer recurrence the food and drug administration said it approved the first test designed to determine the likelihood of breast cancer returning within five to years after a womans initial cancer the test known as the mammaprint test tests genes in order to predict whether existing cancer will spread to other parts of the body the test is made by agendia a closely held company in amsterdam the information obtained by the test can help doctors and patients decide which options are best to treat the cancer 
